Triple-negative breast cancer (TNBC), characterized by negative expression of ER, PR, and HER2, comprises ~15% of all breast cancers5, and shows a poor prognosis due to the high rates of local and systemic relapse and the lack of available endocrine or molecularly targeted treatments6–8. This evidence concerns the gene PGR and triple-negative breast carcinoma.